CXCR3 and breast carcinoma: Simultaneous expressions of CXCL10 and CXCR3 in breast cancer cell lines additionally lead to CXCL10-dependent proliferation of CXCR3-positive cells and treatments using CXCR3 antagonists, and ligand-neutralizing antibodies inhibit metastasis in melanoma and breast cancer in mice [45–47].